Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Leases (2019 - 2022)

Historic Current Leases for Aytu Biopharma (AYTU) over the last 4 years, with Q1 2022 value amounting to $1.2 million.

  • Aytu Biopharma's Current Leases rose 3206.94% to $1.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.2 million, marking a year-over-year increase of 3206.94%. This contributed to the annual value of $940000.0 for FY2021, which is 21333.33% up from last year.
  • According to the latest figures from Q1 2022, Aytu Biopharma's Current Leases is $1.2 million, which was up 3206.94% from $1.2 million recorded in Q4 2021.
  • Over the past 5 years, Aytu Biopharma's Current Leases peaked at $1.2 million during Q1 2022, and registered a low of $79362.0 during Q3 2019.
  • Over the past 4 years, Aytu Biopharma's median Current Leases value was $605442.5 (recorded in 2020), while the average stood at $597072.3.
  • Per our database at Business Quant, Aytu Biopharma's Current Leases skyrocketed by 2115.64% in 2020 and then surged by 106992.31% in 2021.
  • Quarter analysis of 4 years shows Aytu Biopharma's Current Leases stood at $82755.0 in 2019, then rose by 21.16% to $100263.0 in 2020, then soared by 1069.92% to $1.2 million in 2021, then increased by 2.56% to $1.2 million in 2022.
  • Its Current Leases stands at $1.2 million for Q1 2022, versus $1.2 million for Q4 2021 and $1.1 million for Q3 2021.